Last updated: February 16, 2026
Overview:
NDC 24208-0629 pertains to a branded biologic product marketed under the name Zynlonta (loncastuximab tesirine-lpyl), developed by Adaptive Biotechnologies and DACFP LLC. It is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Market penetration and pricing strategies are primarily influenced by competitive options, regulatory status, and treatment adoption patterns.
Market Landscape & Key Factors
1. Target Population & Epidemiology:
The DLBCL patient population in the U.S. approximates 20,000 annually, with relapsed/refractory cases constituting about 7,000—9,000 patients per year. The market segment for Zynlonta focuses on this subset.
2. Competitive Environment:
Existing therapies for relapsed/refractory DLBCL include CAR T-cell therapies (Yescarta, Kymriah, Breyanzi), antibody-drug conjugates (Adcetris), and chemotherapies. Zynlonta faces competition primarily from these well-established treatments. The oral agent Polivy (polatuzumab vedotin) also targets relapsed/refractory DLBCL.
3. Market Adoption Factors:
- Line of Therapy: Positioned as a second-line or later treatment.
- Route of Administration: Intravenous, impacting healthcare setting and administration costs.
- Reimbursement and Pricing: Medicare and private insurances play a role; pricing depends on negotiated discounts and insurer policies.
- Clinical Data: Efficacy and safety profiles influence prescriber confidence and market share.
4. Regulatory & Policy Influences:
Late 2022 FDA approval has enabled initial market entry. Future updates on reimbursement policies, billing codes, and potential designation as a second- or third-line treatment guide market expansion.
Current Market Price & Benchmarking
1. Price Metrics:
As of Q1 2023, the wholesale acquisition cost (WAC) for Zynlonta is approximately $6,200 per 50 mg vial. The typical treatment course involves multiple doses, with an estimated total treatment cost ranging from $125,000 to $150,000 per patient.
2. Pricing Compared to Competitors:
- Yescarta: Approximately $393,000 per dose (up to $400,000+ per cycle).
- Polivy: About $25,000 to $30,000 per cycle, with multiple cycles typically required.
- Adcetris: Around $6,700 per 50 mg vial, similar dosage forms but broader indications.
Zynlonta's price positions it between targeted chemotherapies and CAR T-cell therapies, reflecting its novel mechanism and early market position.
Projected Market Volume & Revenue
| Year |
Estimated Patients Treated |
Market Penetration |
Revenue Estimate |
| 2023 |
1,200 |
15% |
$180 million |
| 2024 |
2,400 |
25% |
$360 million |
| 2025 |
3,600 |
30% |
$540 million |
Assumptions:
- Growth driven by increased awareness, expanded approvals, and clinical data.
- Market share increases gradually as physicians adopt Zynlonta parallel to existing therapies.
- Discounting for negotiated rebate and payer discounts reduces net price.
Pricing Strategy Considerations
- Value-Based Pricing: Focus on clinical benefits over competitors to justify premium pricing.
- Rebate & Discount Management: Negotiations with insurers are likely to reduce net price by 20-25%.
- Access & Reimbursement Policies: Navigating Centers of Excellence and specialty pharmacy inclusion will impact sales.
Regulatory & Policy Outlook
- Potential for Expanded Indications: Additional approvals could increase addressable market.
- Reimbursement Codes: Likely covered under existing cancer treatment billing codes (e.g., CPT, HCPCS), with potential for new codes to optimize reimbursement.
- Pricing Levers: Price adjustments could occur depending on payer negotiations and cost-effectiveness data.
Key Takeaways
- Zynlonta's current U.S. wholesale price is approximately $6,200 per vial, with total treatment costs around $125,000-$150,000.
- Market entry faces competition from CAR T-cell therapies and antibody-drug conjugates, but it offers a differentiated, non-cell therapy option.
- Estimated U.S. market revenue could reach $540 million by 2025, assuming increasing adoption.
- Price projections hinge on reimbursement negotiations and clinical adoption rates.
FAQs
Q1: What factors influence the price of Zynlonta?
Price is influenced by clinical efficacy, competitive positioning, payer negotiations, and treatment complexity.
Q2: How does Zynlonta compare in pricing to similar therapies?
It is less costly than CAR T-cell therapies but more expensive than antibody-conjugates like Polivy, reflecting its phase of adoption.
Q3: What is the potential market size for Zynlonta?
Approximately 7,000-9,000 relapsed/refractory DLBCL patients annually in the U.S.
Q4: Are there upcoming regulatory or policy changes that could affect pricing?
Expanded indications, new reimbursement codes, and guidelines on pricing transparency may influence future pricing.
Q5: How are discounts affecting the net revenue for Zynlonta?
Negotiated rebates and discounts with insurers can reduce net pricing by 20-25%, impacting revenue projections.
References
- U.S. FDA. Zynlonta (loncastuximab tesirine-lpyl) approval announcement, 2022.
- SSR Healthcare Market Reports, 2023.
- IQVIA. U.S. Pharmaceutical Pricing Data, 2022.
- Centers for Medicare & Medicaid Services. HCPCS and CPT billing codes, 2023.
- EvaluatePharma. Oncology drug market outlook, 2023.
